MEDPAL AI is trading 11.02% down at £6.30 after reversing sharply from its recent rally, with the decline appearing consistent with profit-taking and concerns over additional equity dilution.
- On September 9, 1,075,872 new shares linked to the eMARx acquisition and management awards were admitted, increasing issued shares to 779,118,302.
- MedPal also announced 40 million CEO options.
- Broader healthcare weakness and risk-off markets added pressure; available coverage does not explicitly confirm causation between the announcements and the intraday decline.